Lustig R A, DeMare P A, Kramer S
Cancer. 1976 Jun;37(6):2703-8. doi: 10.1002/1097-0142(197606)37:6<2703::aid-cncr2820370620>3.0.co;2-h.
Oral methotrexate (MTX) was administered to a group of 48 patients with advanced head and neck tumors prior to radiation therapy in a nonrandomized manner. A second group of 75 similar patients were randomized to intravenous (i.v.) MTX plus radiation or radiation alone. Three-year survival rates by life table analysis show no significant statistical difference between i.v. MTX plus radiation or radiation alone. Those treated with oral MTX plus radiation have a statistically significant improved survival. The degree of tumor regression in the oral MTX group was correlated with survival. No similar correlation could be found in the intravenous MTX group. The use of either form of MTX correlated with a lower rate of distant metastasis.
以非随机方式对一组48例晚期头颈肿瘤患者在放疗前给予口服甲氨蝶呤（MTX）。将另一组75例相似患者随机分为静脉注射（i.v.）MTX加放疗组或单纯放疗组。通过生命表分析得出的三年生存率显示，静脉注射MTX加放疗组与单纯放疗组之间无显著统计学差异。口服MTX加放疗组的患者生存率有统计学意义的显著提高。口服MTX组的肿瘤消退程度与生存率相关。在静脉注射MTX组中未发现类似的相关性。两种形式的MTX的使用都与较低的远处转移率相关。
